


In the Claims:


Please amend the claims as follows:

Claims 1-109 (Cancelled).

1 ~~110.~~ (Currently Amended) ~~The A diagnostic imaging contrast agent according to claim~~
107 having the following structure:




2 ~~111.~~ (Currently Amended) ~~The A diagnostic imaging contrast agent according to claim~~
108 having the following structure:




3 ~~112.~~ (Currently Amended) ~~The A diagnostic imaging contrast agent according to claim~~
109 having the following structure:

T,0680




- 4
113. (Currently Amended) The A diagnostic imaging contrast agent according to claim 109 having the following structure:

B T,0681




- 5
114. (Currently Amended) The A diagnostic imaging contrast agent according to claim 109 having the following structure:

T,0682



- 6
115. (Currently Amended) The A diagnostic imaging contrast agent according to claim 109 having the following structure:

T,0690




, wherein Me=methyl.

7

116. (Currently Amended) The A diagnostic imaging contrast agent according to claim 109 having the following structure:

B1

T,0691




, wherein Ph=phenyl.

8

117. (Currently Amended) The A diagnostic imaging contrast agent according to claim 109 having the following structure:

T,0692



, wherein Ph=phenyl.

Claims 118-134 (Cancelled).

Applicant : Thomas J. McMurphy et al.
Serial No. : 10/034,522
Filed : December 20, 2001
Page : 5 of 6

Attorney's Docket No.: 13498-005002 / MET-4

✓ ⁹ ~~135~~. (Currently Amended) A pharmaceutical composition comprising a diagnostic imaging contrast agent according to any of claims 103, ¹¹⁻⁸ ~~110-117~~, and a carrier, adjuvant, or vehicle.

B2 ¹⁰ ~~136~~. (Original) The pharmaceutical composition according to claim ⁹ ~~135~~, further comprising a free organic ligand or a pharmaceutically acceptable salt thereof.